2017 Symposium

2016 Symposium

2015 Symposium

2015 Agenda and Bios

2015 Symposium Photos

2014 Symposium

2014 Agenda and Bios

2013 Featured Talks

2013 Symposium Photos

Previous Symposia

2014 Featured Talks » Zeroing in an oncogenic driver: The Rapid Evolution of Targeted Therapies for Anaplastic Lymphoma Kinase-Positive Lung Cancer



Zeroing in an oncogenic driver: The Rapid Evolution of Targeted Therapies for Anaplastic Lymphoma Kinase-Positive Lung Cancer


Valeria Fantin, PhD
Pfizer




Valeria Fantin, PhD
Vice President, Tumor Cell Biology
Pfizer Inc.


Valeria Fantin is currently Vice President of Tumor Cell Biology at Pfizer. She received her PhD in Molecular and Cellular Biology from Dartmouth, where she worked on insulin and IGF1 signaling. She went on to do her postdoctoral training in the department of Genetics at Harvard Medical School. The focus on her research work was breast cancer, and in particular in oncogene-driven metabolic rewiring. Prior to joining Pfizer, Valeria held positions at Merck, Ariad Pharmaceuticals and Agios Pharmaceuticals leading target validation as well as drug discovery and development projects in diverse areas including signal transduction, epigenetics and cancer metabolism.